Corion Biotech received positive feedback from FDA Agency during the INTERACT meeting. Corion Biotech received positive feedback from FDA Agency during the INTERACT meeting.amministratorecorion2024-02-29T18:57:21+01:0011/01/2024|Read More
Corion Biotech signed an agreement with “Officina Farmaceutica” University of Turin Cell factory (Italy) for GMP production of CB-ChMF-11 for treatment of Preeclampsia. Corion Biotech signed an agreement with “Officina Farmaceutica” University of Turin Cell factory (Italy) for GMP production of CB-ChMF-11 for treatment of Preeclampsia.amministratorecorion2024-02-29T18:51:33+01:0001/07/2021|Read More
Corion Biotech received European Medicines Agency (EMA) Orphan Drug Designation for Preeclampsia. Corion Biotech received European Medicines Agency (EMA) Orphan Drug Designation for Preeclampsia.amministratorecorion2024-02-29T18:53:13+01:0012/05/2021|Read More
LIFTT and FINDE 1Mln round investment LIFTT and FINDE 1Mln round investmentamministratorecorion2021-09-07T12:01:36+02:0031/07/2020|Read More
Corion Biotech granted patent in Europe for the treatment of epithelial tumors by a placental mesenchymal cells-derived biological product. Corion Biotech granted patent in Europe for the treatment of epithelial tumors by a placental mesenchymal cells-derived biological product.amministratorecorion2024-02-29T18:55:13+01:0020/01/2018|Read More
Corion Biotech granted patent in Europe for the treatment of Preeclampsia with a placenta-derived biological product. Corion Biotech granted patent in Europe for the treatment of Preeclampsia with a placenta-derived biological product.amministratorecorion2024-02-29T18:56:54+01:0012/03/2016|Read More
